

ForPatients

by Roche

Alzheimer's Disease (AD)

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Trial Status
Completed

Trial Runs In
0 Countries

Trial Identifier
NCT03977584 BN40199

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This substudy will evaluate the effect of crenezumab on the longitudinal tau burden in a subgroup of preclinical Presenilin1 (PSEN1) E280A mutation carriers and non-carriers, who were enrolled in study NCT01998841 (GN28352). Participants will receive up to three intravenous (IV) injections of [¹⁸F] Genentech Tau Probe 1 (GTP1) and will undergo a tau positron emission tomography (PET) scan after each IV injection of [¹⁸F]GTP1. The purpose of this substudy is to increase the understanding of disease progression in the preclinical stage of familial Alzheimer's Disease (AD).

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03977584 BN40199
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=30 Years & <= 60 Years

Healthy Volunteers
No
